Paul D. Rubin

Paul D. Rubin is a partner based in the Washington, D.C. office and is the Co-Chair of the firm’s Healthcare & Life Sciences Group and the Chair of the FDA Regulatory practice. His practice focuses on FDA/FTC regulatory matters.

Mr. Rubin represents FDA-regulated drug, device and consumer product companies on a wide range of issues ranging from strategic regulatory counseling to complex compliance and enforcement matters. He also routinely conducts regulatory due diligence for private equity funds and strategic acquirers in corporate transactions.

In addition to his FDA practice, Mr. Rubin also has substantial experience helping clients navigate complex advertising/promotion and privacy-related issues, including FTC investigations, negotiating FTC settlements/consent decrees, disputes before the National Advertising Division of the BBB National Programs (NAD) and advertising lawsuits under Section 43(a) of the Lanham Act. Mr. Rubin also has considerable experience advising consumer product companies on CPSC-related compliance, including Section 15(b) submissions and “Fast Track Recalls.”